AccuPowe COVID-19 Real-Time RT-PCR Kit is an in vitro diagnostic kit that helps diagnose COVID-19 infections, detects SARS-CoV-2 (E gene and RdRp gene) RNA from a suspected infection patient's sample (such as sputum, nasopharyngeal swab, oropharyngeal swab) through Real-Time Polymerase chain reaction(PCR) using ExiStation Universal MDx system.
I am representing SD Biosensor from South Korea that manufactures US FDA EUA approved Standard M nCo V Real-Time Detection Kit (COVID Testing kit). We have received US FDA EUA approval to export Covid 19 detection kit in April and can directly export from Korea.
SD Biosensor is one of the few companies that has received US FDA approvals and have already sold 1.5 million testing units to US government (Based on US government reaching out to South Korea Government for help with procuring Covid Testing kits).
I'm currently in Seoul, South Korea but I'm a US citizen helping SD Biosensor as an agent to help buyers procure these testing kits. This company has capability to manufacture over 600,000 testing units a day and have enough supplies readily available for an immediate export.
Please email me at Jinsoo.park@att.net to receive US FDA EUA Approval and product information. rapid test kits which are not FDA approved are in the low to mid $20 range and the price for FDA EUA approved standard test kits are around high $20s to low $30s and depending on the contract length and quantity we have some room for negotiation. Also these kits have to be refrigerated shipped so there will be some additional cost for this.
I am representing SD Biosensor from South Korea that manufactures US FDA EUA approved Standard M nCo V Real-Time Detection Kit (COVID Testing kit). We have received US FDA EUA approval to export Covid 19 detection kit in April and can directly export from Korea.
SD Biosensor is one of the few companies that has received US FDA approvals and have already sold 1.5 million testing units to US government (Based on US government reaching out to South Korea Government for help with procuring Covid Testing kits).
I'm currently in Seoul, South Korea but I'm a US citizen helping SD Biosensor as an agent to help buyers procure these testing kits. This company has capability to manufacture over 600,000 testing units a day and have enough supplies readily available for an immediate export.
Please email me at Jinsoo.park@yahoo.com to receive US FDA EUA Approval and product information. rapid test kits which are not FDA approved are in the low to mid $20 range and the price for FDA EUA approved standard test kits are around high $20s to low $30s and depending on the contract length and quantity we have some room for negotiation. Also these kits have to be refrigerated shipped so there will be some additional cost for this.
o Product Name
- Gendbody COVID-19 AG Test Kit
- Gendbody COVID-19 AG Home Test Kit
- Gendbody COVID-19 lgG/lgM
o Price (USD) : 2.5$ (FOB) - Can be discussed up to order Qty
- CIF : Can be discussed
o Certification : CE,FDA
o MOQ : 1,000 pcs
o Payment : L/C, TT
o Delivery Time
- Up to Qty
- Capacity : 3,000,000pcs / 1week
Genbody Covid-19 AG Home Test Kit is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein from SARS-COV-2 from individual's nasal specimen with or without COVID-19 symptoms.
* High Accuracy, Specificity and Sensitivity
* No need instrument, Get Results in 15 Minutes
* Room Temperature Storage
* Sample: Saliva Sample
* Detect the presence of viral proteins
* Identify acute or early infection
1 Test/Kit
***** WE ARE THE AUTHORIZED DISTRIBUTOR IN MALAYSIA ******
***** WELCOME RESELLERS ******
COVID-19 IgM/IgG Antibody Detection Kit (Colloidal Gold Immunochromatography) is suitable for the qualitative detection of COVID-19 by detecting SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. Common signs of infection with SARS-CoV-2 include respiratory symptoms, fever, cough, shortness of breath, and dyspnea. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death. SARS-CoV-2 can be excreted through respiratory secretions or transmitted through oral fluids, sneezing, physical contact, and through air droplets
Due to contractual obligations to the federal government, Current suppliers have increased costs and limited production of all point of care tests without notice. We have great news! To shield our customers from excessive price increases as well as provide immediate availability, we have secured multiple FDA EUA rapid antigen test kit options. These tests have similar and/or better accuracy along with individual buffer bottles. We are currently able to provide three options: Clarity-Sienna, Indicaid and Celltrion DiaTrust kits. We work directly with the distributor and can supply by the pallet or case with pricing as low as $6.00 per kit.
Use of this test with all authorized specimen types is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform moderate or high complexity tests.
This test is also authorized for use with fingerstick whole blood specimens only at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
The CLIA Waived COVID-19 IgG/IgM Rapid Test Device is an in vitro immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only.
Indication:
Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories.
About Test Device
EUA Authorized
CE Mark
Test does NOT give positive or negative result for COVID-19 virus. This is an antibody test, it only indicates past or recent infection.
Read Results in 15 Minutes
9 Month Expiration from Date of Manufacture
Contents
The CareStart COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal or anterior nasal swab specimens directly collected from individuals who are either suspected of COVID-19 by their healthcare provider within the first five days of symptom onset or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
Lateral flow assay
Detect SARS-CoV-2 nucleocapsid protein antigen
Rapid results within 10-15 minutes
Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
For use under the Emergency Use Authorization (EUA) only
For in vitro diagnostic use only
For prescription use only
For use with direct anterior nasal and nasopharyngeal swab specimens
Clinical Performance
93.75% PPAa and 99.32% NPAb when used with nasopharyngeal swab
87.18% PPAa and 100% NPAb when used with anterior nasal swab
The COVID-19 IgG/IgM Rapid Test Device is an in vitro Immunoassay for the direct and qualitative detection of anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG in human whole blood, serum, or plasma. The test is for professional use only.
Indication:
Qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human venous whole blood (sodium EDTA), serum, or plasma (sodium EDTA). Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
About Test Device
Gives Positive or Negative Result for COVID-19 IgM/IgG antibodies
Read Results in 15 Minutes
Contents of each box
